Breaking News Instant updates and real-time market news.

UMRX

Unum Therapeutics

$1.78

-0.01 (-0.56%)

16:10
08/12/19
08/12
16:10
08/12/19
16:10

Unum Therapeutics reports Q2 EPS (34c), consensus (40c)

Reports Q2 revenue $3.14M, consensus $3.2M."During the quarter, we advanced our preclinical and clinical pipeline programs that are designed to improve the targeting and functionality of T cells to expand their use in hematologic and solid tumor cancers," said Chuck Wilson, President and Chief Executive Officer of Unum. "Today, we reported preliminary results from Cohort 3 of the Phase 1 trial with ACTR707 in patients with relapsed or refractory non-Hodgkin lymphoma. We are very encouraged by the results from this trial that support our progress towards developing a competitive program with complete responses achieved in five of the 14 patients treated and no reported adverse events of cytokine release syndrome or severe neurotoxicity. Patient enrollment in Cohort 4 is now complete and we anticipate providing results from this cohort later this year. Our ACTR and BOXR platform initiatives in solid tumors also continued during the quarter, with Phase 1 trial enrollment activities progressing on our ACTR707 program in patients with HER2+ solid tumors. Our BOXR platform is designed to improve the functionality of engineered T cells by incorporating a "bolt-on" transgene to overcome resistance of the solid tumor microenvironment to T cell attack, and we are pleased to advance our first candidate from this platform, BOXR1030, towards clinical trials."

  • 12

    Aug

  • 09

    Sep

UMRX Unum Therapeutics
$1.78

-0.01 (-0.56%)

07/03/19
MSCO
07/03/19
NO CHANGE
Target $18
MSCO
Overweight
Clinical hold not a 'major event' for Unum Therapeutics, says Morgan Stanley
After Unum Therapeutics announced that the FDA has placed a clinical hold on the Phase 1 trial ATTCK-20-2 evaluating Unum's ACTR087 in combination with rituximab, Morgan Stanley analyst Matthew Harrison said he does not view this as a "major event" given that management had previously de-prioritized the program during its earnings call last November. Lead program ACTR707 has reported no DLTs or serious adverse events of CRS or neurotoxicity through the first three patient cohorts as of May 7, noted Harrison, who would argue that ACTR707 "clearly has a different safety profile" than ACTR087. He maintains an Overweight rating on Unum Therapeutics shares.
07/03/19
RHCO
07/03/19
NO CHANGE
Target $6
RHCO
Buy
Unum Therapeutics price target lowered to $6 from $10 at SunTrust
SunTrust analyst Peter Lawson lowered his price target on Unum Therapeutics to $6 after yesterday's FDA announcement of a clinical hold on its Phase 1 trial ATTCK-20-2 evaluating ACTR087 in combination with rituximab. The analyst is retaining a Buy rating on the stock however, stating that his discussions with the management indicated the program was already de-prioritized in November of 2018 "in favor of the '707 construct", and the hold should yield a limited read through to other programs.
07/03/19
COWN
07/03/19
NO CHANGE
COWN
Market Perform
Unum Therapeutics clinical hold not an issue, says Cowen
Cowen analyst Yaron Werber noted the FDA placed a clinical hold on ACTR087 adding to ongoing concerns about the potential of its platform given lackluster efficacy data. The analyst said the hold is not an issue as it was deprioritized and the prospects for the stock may lie in the BOXR platform. Werber maintained his Market Perform rating on Unum Therapeutics shares.
07/03/19
HCWC
07/03/19
NO CHANGE
Target $18
HCWC
Buy
Unum Therapeutics shares overreacted to clinical hold, says H.C. Wainwright
Unum Therapeutics shares overreacted yesterday to news of a clinical hold on the Phase 1 trial ATTCK-20-2, which may provide an attractive entry point, H.C. Wainwright analyst Andrew Fein tells investors in a research note. The analyst says that although the clinical hold raises concerns on potential "narrower-than-expected therapeutic window" of ACTR-087 in B-cell malignancies, his comfort in a positive outlook of ATTCK-20-02 and ACTR-T cells in general is derived from the fact that approved CAR-T therapies, Kymriah and Yescarta, are both associated with similar serious adverse events. The analyst reiterates a Buy rain on Unum Therapeutics with an $18 price target ahead of the company's multiple data in 2019.

TODAY'S FREE FLY STORIES

ONE

OneSmart

$7.03

-0.355 (-4.81%)

05:36
08/19/19
08/19
05:36
08/19/19
05:36
Hot Stocks
OneSmart announces CEO share purchase plan »

OneSmart announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WB

Weibo

$37.05

1.69 (4.78%)

05:34
08/19/19
08/19
05:34
08/19/19
05:34
Earnings
Breaking Earnings news story on Weibo »

Weibo sees Q3 revenue up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

WB

Weibo

$37.05

1.69 (4.78%)

05:34
08/19/19
08/19
05:34
08/19/19
05:34
Earnings
Weibo reports Q2 EPS 68c, consensus 59c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

SINA

Sina

$37.66

1.97 (5.52%)

05:32
08/19/19
08/19
05:32
08/19/19
05:32
Earnings
Sina reports Q2 EPS 76c, consensus 47c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

05:25
08/19/19
08/19
05:25
08/19/19
05:25
General news
FX Action: The yen has nudged lower »

FX Action: The yen has…

05:20
08/19/19
08/19
05:20
08/19/19
05:20
General news
FX Action: The yen has nudged lower »

FX Action: The yen has…

TWTR

Twitter

$40.58

0.47 (1.17%)

04:55
08/19/19
08/19
04:55
08/19/19
04:55
Conference/Events
Twitter management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 20

    Aug

  • 20

    Aug

  • 24

    Sep

AVY

Avery Dennison

$113.94

2.305 (2.06%)

04:55
08/19/19
08/19
04:55
08/19/19
04:55
Conference/Events
Avery Dennison management to meet with Loop Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 20

    Aug

  • 21

    Aug

CHH

Choice Hotels

$88.24

0.7 (0.80%)

04:55
08/19/19
08/19
04:55
08/19/19
04:55
Conference/Events
Choice Hotels management to meet with Morgan Stanley »

Group Luncheon Meeting to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

PAYS

Paysign

$13.94

0.12 (0.87%)

04:55
08/19/19
08/19
04:55
08/19/19
04:55
Recommendations
Paysign analyst commentary  »

Paysign management to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 20

    Aug

  • 21

    Aug

  • 26

    Aug

  • 27

    Aug

  • 28

    Aug

APHA

Aphria

$6.17

0.23 (3.87%)

04:55
08/19/19
08/19
04:55
08/19/19
04:55
Conference/Events
Aphria management to meet with Seaport Global »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 20

    Aug

MCO

Moody's

$214.29

4.42 (2.11%)

04:55
08/19/19
08/19
04:55
08/19/19
04:55
Conference/Events
Moody's management to meet with MKM Partners »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 20

    Aug

NCMGY

Newcrest Mining

$0.00

(0.00%)

04:55
08/19/19
08/19
04:55
08/19/19
04:55
Conference/Events
Newcrest Mining management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 20

    Aug

  • 21

    Aug

NPO

EnPro

$61.93

2.13 (3.56%)

04:55
08/19/19
08/19
04:55
08/19/19
04:55
Conference/Events
EnPro management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 20

    Aug

  • 21

    Aug

RMD

ResMed

$134.45

2.06 (1.56%)

04:55
08/19/19
08/19
04:55
08/19/19
04:55
Conference/Events
ResMed management to meet with UBS »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 26

    Aug

  • 05

    Nov

  • 06

    Nov

ZNGA

Zynga

$5.56

0.025 (0.45%)

04:55
08/19/19
08/19
04:55
08/19/19
04:55
Conference/Events
Zynga management to meet with Wedbush »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 13

    Nov

CCMP

Cabot Microelectronics

$122.73

4.24 (3.58%)

04:55
08/19/19
08/19
04:55
08/19/19
04:55
Conference/Events
Cabot Microelectronics management to meet with Loop Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

04:55
08/19/19
08/19
04:55
08/19/19
04:55
General news
Breaking General news story  »

3-Month Bill Auction to…

QMCO

Quantum

$0.00

(0.00%)

04:55
08/19/19
08/19
04:55
08/19/19
04:55
Conference/Events
Quantum management to meet with B. Riley FBR »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 20

    Aug

  • 21

    Aug

  • 12

    Sep

GKOS

Glaukos

$63.02

2.385 (3.93%)

04:55
08/19/19
08/19
04:55
08/19/19
04:55
Conference/Events
Glaukos management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 26

    Aug

  • 04

    Sep

  • 13

    Nov

04:55
08/19/19
08/19
04:55
08/19/19
04:55
General news
Breaking General news story  »

6-Month Bill Auction to…

BCEI

Bonanza Creek

$22.76

1.61 (7.61%)

04:55
08/19/19
08/19
04:55
08/19/19
04:55
Conference/Events
Bonanza Creek management to meet with SunTrust »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 20

    Aug

FFIN

First Financial

$31.15

0.78 (2.57%)

04:55
08/19/19
08/19
04:55
08/19/19
04:55
Recommendations
First Financial analyst commentary  »

First Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 23

    Sep

  • 26

    Sep

  • 27

    Sep

SF

Stifel Financial

$52.18

0.925 (1.80%)

04:55
08/19/19
08/19
04:55
08/19/19
04:55
Conference/Events
Stifel Financial management to meet with JMP Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 20

    Aug

AU

AngloGold

$21.04

0.7 (3.44%)

04:55
08/19/19
08/19
04:55
08/19/19
04:55
Conference/Events
AngloGold management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 20

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.